{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-058254","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.122649+00:00","generated_at":"2026-06-08T23:18:50.763849+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Acadia Q3 2023 record revenue $211.7M; DAYBUE launch strong at $66.9M, NUPLAZID grows","bullets":["Q3 total revenue $211.7M; DAYBUE net sales $66.9M (first full quarter), NUPLAZID $144.8M, up from $130.7M YoY","Net loss $65.2M ($0.40 per share) vs $27.2M loss YoY; includes $100M upfront for worldwide DAYBUE rights","Full-year 2023 guidance: NUPLAZID net sales $537.5-545M; R&D $340-350M; SG&A $390-400M","Plans to start Phase 3 for ACP-101 (Prader-Willi) and Phase 2/3 for ACP-204 (Alzheimer's psychosis) in Q4 2023","Appoints Albert Kildani as SVP IR and Stephanie Kim as SVP Regulatory Affairs"],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-058254","json":"https://secwatch.observer/filing/0000950170-23-058254.json","markdown":"https://secwatch.observer/filing/0000950170-23-058254.md","text":"https://secwatch.observer/filing/0000950170-23-058254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023058254/0000950170-23-058254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023058254/acad-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:18:50.763849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e60079c815a12e68b7283ee783c1c245e768228","claim":"ACADIA PHARMACEUTICALS INC reported the third quarter ended September 30, 2023 results: revenue $211.7 million, net income $65.2 million, EPS $0.40 per common share. Guidance initiated.","evidence_excerpt":"Total revenues, comprised of net product sales from NUPLAZID and DAYBUE were $211.7 million for the three months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023058254/0000950170-23-058254-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$211.7 million"},{"label":"Net income","value":"$65.2 million"},{"label":"EPS","value":"$0.40 per common share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"860ad98636ae47e4bdff016448055c46c0e2fed8","claim":"ACADIA PHARMACEUTICALS INC reported the nine months ended September 30, 2023 results: revenue $495.4 million, net income $107.1 million, EPS $0.65 per common share. Guidance initiated.","evidence_excerpt":"and were $495.4 million for the nine months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023058254/0000950170-23-058254-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2023"},{"label":"Revenue","value":"$495.4 million"},{"label":"Net income","value":"$107.1 million"},{"label":"EPS","value":"$0.65 per common share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}